↓ Skip to main content

Cochrane Database of Systematic Reviews

Temozolomide for high grade glioma

Overview of attention for article published in Cochrane database of systematic reviews, April 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (59th percentile)

Mentioned by

news
2 news outlets
facebook
1 Facebook page
wikipedia
7 Wikipedia pages

Citations

dimensions_citation
138 Dimensions

Readers on

mendeley
422 Mendeley
Title
Temozolomide for high grade glioma
Published in
Cochrane database of systematic reviews, April 2013
DOI 10.1002/14651858.cd007415.pub2
Pubmed ID
Authors

Michael G Hart, Ruth Garside, Gabriel Rogers, Ken Stein, Robin Grant

Abstract

High grade glioma (HGG) is an aggressive form of brain cancer. Treatment of HGG usually entails biopsy, or resection if safe, followed by radiotherapy. Temozolomide is a novel oral chemotherapy drug that penetrates into the brain and purportedly has a low incidence of adverse events.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 422 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 2 <1%
Germany 1 <1%
France 1 <1%
Netherlands 1 <1%
Japan 1 <1%
United States 1 <1%
Unknown 415 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 64 15%
Student > Bachelor 56 13%
Student > Ph. D. Student 41 10%
Researcher 39 9%
Student > Doctoral Student 39 9%
Other 70 17%
Unknown 113 27%
Readers by discipline Count As %
Medicine and Dentistry 143 34%
Biochemistry, Genetics and Molecular Biology 28 7%
Agricultural and Biological Sciences 26 6%
Pharmacology, Toxicology and Pharmaceutical Science 22 5%
Nursing and Health Professions 19 5%
Other 55 13%
Unknown 129 31%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 February 2021.
All research outputs
#2,460,931
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#4,968
of 11,499 outputs
Outputs of similar age
#20,140
of 204,400 outputs
Outputs of similar age from Cochrane database of systematic reviews
#99
of 248 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.0. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 204,400 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 248 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.